Sareum’s small molecule drug discovery expertise builds value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies.
01 July 2020
03 June 2020
02 June 2020
02 June 2020
The potential of Sareum's SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19
BIO Digital, June 2020 (Slides)
Proactive Investors, June 2020 (Video)
BioTrinity, April 2020 (Video, Slides)
Half-yearly Results, March 2020 (Slides)
Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
